D Provan, AC Newland… - New England Journal of …, 2011 - Mass Medical Soc The Authors Reply: Wagle and Aragon-Ching both make the point that there were alternative explanations for the reductions in the use of ADT that we noted other than financial incentive. We agree and acknowledged a number of other po- tential contributing factors ... Cited by 1 - Related articles - All 2 versions
R Rayment, SJ Brunskill, PW Soothill… - … of systematic reviews …, 2011 - ncbi.nlm.nih.gov BACKGROUND: Fetomaternal alloimmune thrombocytopenia results from the formation of antibodies by the mother which are directed against a fetal platelet alloantigen inherited from the father. The resulting fetal thrombocytopenia (reduced platelet numbers) may cause bleeding, ... Cited by 2 - Related articles
M Stolla, L Stefanini, P André, TD Ouellette… - Blood, 2011 - ncbi.nlm.nih.gov Platelet activation via Fcγ receptor IIA (FcγRIIA) is a critical event in immune-mediated thrombocytopenia and thrombosis syndromes (ITT). We recently identified signaling by the guanine nucleotide exchange factor CalDAG-GEFI and the ADP receptor P2Y12 as independent pathways ...
TW Du Clos… - US Patent 20,110,152,202, 2011 - freepatentsonline.com The present invention relates to the use of a mutant CRP molecule in which tyrosine 175 is replaced by leucine (Y175L CRP) or the leucine 176 is replaced by glutamic acid (L176E CRP) for the treatment of various disease states and conditions associated with SLE, including lupus ... Related articles - Cached
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
